Augusto Villegas, MD
Medical Oncology · Fleming Island, FLNPI 1003804485
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 66.8% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $36,830 and has fallen 89.3% since, to $3,939 in 2025. Among medical oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 834 payments — averaging $112.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$63K
- Seagen Inc.$7K
- Astrazeneca UK Limited$3K
- Novartis$3K
- Sanofi$2K
- Karyopharm Therapeutics Inc.$2K
- plus $13K from 54 others
Across 81 payments — averaging $6432.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$324K
- GSK$115K
- Beigene, Ltd.$58K
- E.r. Squibb & Sons, L.L.C.$9K
- Myriad Genetic Laboratories, Inc.$8K
- Pfizer$6K
- plus $237 from 1 others
What the payments were for
- Consulting fees$39,74442%
- Speaking & faculty fees$33,82536%
- Travel & lodging$4,9985%
- Food & beverage$15,33616%
- Education$1860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,087 in reported general payments places this provider in the 90th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 28 | $536,253 |
| BrukinsaZanubrutinib | 30 | $448,784 |
| TagrissoOsimertinib Mesylate | 19 | $315,996 |
| VerzenioAbemaciclib | 21 | $309,609 |
| ImbruvicaIbrutinib | 18 | $294,550 |
| InlytaAxitinib | 18 | $221,482 |
| CalquenceAcalabrutinib Maleate | 11 | $170,048 |
| VenclextaVenetoclax | 14 | $132,450 |
| EliquisApixaban | 45 | $42,218 |
| XareltoRivaroxaban | 51 | $41,110 |
| Xtampza ErOxycodone Myristate | 23 | $18,080 |
| Deferasirox | 21 | $6,782 |
| Oxycodone Hcl | 65 | $2,705 |
| Letrozole | 95 | $2,305 |
| Abiraterone Acetate | 12 | $1,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $521 | $536,25328 claims |
| AstraZenecaTagrisso, Calquence | $62,835 | $486,04430 claims |
| Beigene USA, Inc.Brukinsa | $87 | $448,78430 claims |
| Lilly USA, LLCVerzenio | $240 | $309,60921 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $48 | $294,55018 claims |
| PfizerInlyta, Eliquis | $897 | $263,70163 claims |
| AbbVieVenclexta | $247 | $132,45014 claims |
| Johnson & JohnsonXarelto | $459 | $41,11051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Fleming Island
- Jeffrey BubisFleming Island$75K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.